Exa-cel (Casgevy) Price Breakdown: What the $2.2M Sticker Actually Covers in 2026

Exa-cel sells under the brand name Casgevy. It was approved by the FDA for severe sickle cell disease on December 8, 2023, then cleared for transfusion-dependent beta thalassemia five weeks later. It is the first CRISPR-based therapy to reach commercial use in the United States. It is also, by list price, the cheapest of the three gene therapies currently on market for hemoglobin disorders — which says more about the pricing environment than about Vertex's generosity.

About 16,000 Americans have severe sickle cell disease severe enough to qualify for Casgevy. Roughly 60% of them are on Medicaid. That single fact explains why a drug priced at $2.2 million per patient is, in practice, a state-level budget question before it is a clinical one.

What the $2.2 Million Actually Buys

The $2.2 million figure is the wholesale acquisition cost (WAC) for the Casgevy drug product itself. It covers the editing and manufacturing of a patient's own stem cells at Vertex's contracted facility, plus the shipment back to the treatment center. It does not cover any of the 10 to 12 months of clinical work wrapped around that infusion.

The treatment journey runs roughly like this: cell collection via apheresis, myeloablative conditioning with busulfan (a chemotherapy agent that wipes out the patient's existing bone marrow), the Casgevy infusion itself, then four to six weeks of inpatient recovery while the edited cells engraft. Authorized Treatment Centers — a network of 60+ academic hospitals Vertex has credentialed — bill all of that separately.

Internal payer estimates we've reviewed put the full episode-of-care cost between $2.8M and $3.1M. Vertex's own IR materials reference a "total cost of care" range in that zone when modeling payer conversations.

Where the extra $600K–$900K goes

The wrap-around costs break down roughly as: $180K–$240K for apheresis and cell processing logistics, $320K–$410K for the conditioning chemotherapy regimen and associated inpatient days, $140K–$200K for post-infusion monitoring through month six, and another $60K–$90K in outpatient follow-up through month twelve. These are the numbers the Institute for Clinical and Economic Review (ICER) used in its 2024 value assessment, which concluded that Casgevy's net health benefit justifies a price "up to $2.05M" — meaning ICER considered it overpriced by roughly 7% on launch.

How Casgevy Prices Against the Other One-Shot Therapies

Lyfgenia is the more direct Casgevy competitor — same disease, same delivery window, similar engraftment mechanics. Bluebird's $3.1M ask has crumbled in market uptake. As of Vertex's Q4 2025 earnings, Casgevy had outpaced Lyfgenia on total authorized starts by more than 3-to-1 in its first eight quarters, despite both launching within a week of each other.

Part of that is the CRISPR story — payers and ATCs have preferred the edited-base-pair mechanism over Bluebird's lentiviral vector. Part of it is the $900K list-price delta. And part of it is Vertex's operational footprint. Vertex has run commercial launches before; Bluebird is still learning how.

The Medicaid Math — And Why CMS Built a New Payment Model

Medicaid covers roughly 60% of the US sickle cell population. That exposure is the single largest reason the Cell and Gene Therapy Access Model exists. CMS opened enrollment for the model in January 2025. As of March 2026, 33 states and DC have signed on.

The model lets state Medicaid programs negotiate outcomes-based contracts with Vertex and Bluebird — the drug manufacturer refunds a portion of the price if the patient doesn't hit defined clinical benchmarks (reduction in vaso-occlusive crises, transfusion independence, or specified hemoglobin thresholds) within a contracted window. The contracts typically structure 20% to 40% of the drug cost as contingent on those outcomes.

Without the Access Model, a mid-sized state Medicaid program treating 30 sickle cell patients per year would be looking at an incremental $66M to $90M line item. With it, the exposure drops to something states can actually plan against.

What Pharmacy Decision-Makers Should Watch in Q2 2026

Three things are worth tracking this quarter:

First: the Q1 2026 Vertex earnings call (scheduled April 29). Analysts will be watching the number of patients who have completed apheresis versus the number who have actually received their infusion. Capacity at Authorized Treatment Centers — specifically the availability of inpatient conditioning beds — has been the rate-limiting step throughout 2025. If that ratio is improving, revenue guidance for 2026 likely moves up.

Second: ICER's planned Q3 update to its 2024 Casgevy assessment. ICER has flagged that it will revisit its $2.05M price benchmark using post-launch data on durability and complication rates. A downward revision would hand payers negotiating leverage heading into 2027 contracts.

Third: the Casgevy label expansion track. Vertex filed a supplemental BLA in February 2026 seeking approval for patients with less severe sickle cell phenotypes. If approved — likely in late 2026 or Q1 2027 — the addressable US population roughly doubles. That reframes the entire payer math and likely accelerates the next round of CMS model design.

The list price is not the number to watch. The number to watch is whether the Access Model can hold up against that doubled patient pool. If it does, Casgevy becomes a template for how gene therapies reach scale in a Medicaid-dominant population. If it doesn't, 2027 is where the pricing fight gets ugly.